Programme
Home   Overview   Programme/Posters   Speakers/Abstracts   Presentations   Sponsors   Symposium Pictures   Symposium Report   Kinase Links   Meetings   Speakers Articles		Programme as of 15th November 2006 Download the programme Download the posters abstract SUNDAY, 3RD DECEMBER 2006: 14.00 - 19.00:   Registration / Poster setup and poster session 18.00 - 20.00:   Reception and Opening Apero   MONDAY, 4TH DECEMBER 2006: Session I   Chair: Dr. Brian A. Hemmings, Friedrich Miescher Institute for Biomedical Research, Basel 08.30 - 09.00:   Opening Ceremony 09.00 - 09.40:   Prof. Tony Hunter, The Salk Institute, La Jolla, CA, USA The history of the kinome and its use to develop inhibitors 09.40 - 10.20:   Prof. Tony Pawson, Samuel Lunenfeld Research Institute, Toronto, ON, Canada Kinome signalling through regulated protein-protein interactions in normal and cancer cells 10.20 - 10.50:   Coffee Session II   Chair: Prof. Paul Herrling, Head Corporate Research, Novartis International, Basel, Switzerland 10.50 - 11.30:   Prof. Axel Ullrich, Max-Planck-Institute for Biochemistry, Martinsried, Germany Mining the oncokinome 20 years plus: per aspera ad astra of cancer therapy 11.30 - 12.10:   Prof. Joseph Schlessinger, Yale University School of Medicine, New Haven, CT, USA Cell signaling by receptor tyrosine kinases: from bench to bedside 12.10 - 12.50:   Prof. Nancy E. Hynes, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland Targeting the ErbB receptors in cancer 13.00 - 14.30:   Lunch Session III   Chair: Dr. Elisabeth Buchdunger, Novartis Institutes for BioMedical Research, Basel, Switzerland 14.30 - 15.10:   Dr. Kari Alitalo, University of Helsinki, Helsinki, Finland VEGFs and receptors involved in angiogenesis versus lymphangiogenesis 15.10 - 15.50:   Prof. Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden Signalling via receptors for PDGF and TGF-beta - possible targets for tumor therapy 15.50 - 16.30:   Prof. Sir Philip Cohen, MRC, University of Dundee, Scotland, UK Targeting protein kinases for the development of anti-inflammatory drugs 16.30 - 17.00:   Coffee Session IV   Chair: Prof. Bernd Groner, Georg Speyer House, Institute for Biomedical Research, Frankfurt am Main, Germany 17.00 - 17.40:   Dr. Nick Lydon, Granite Biopharma LLC, Wilson, WY, USA From Gleevec to targeting the kinome 17.40 - 18.20:   Dr. Paul Manley, Novartis Institutes for BioMedical Research, Basel, Switzerland Nilotinib: A new Bcr-Abl kinase inhibitor for the treatment of imatinib-resistant CML and GIST 18.20 - 19.00:   Prof. Alex Matter, Novartis Institute for Tropical Diseases (NITD), Singapore, Singapore Kinases as drug targets in infectious diseases 19.00 - 21.00:   Poster session   TUESDAY, 5TH DECEMBER 2006: Session V   Chair: Christoph Moroni, Department Clinical-Biological Sciences, University of Basel, Basel, Switzerland 08.30 - 09.10:   Prof. George Demetri, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA Treating the kinase signalling addiction in solid tumors: lessons learned from GIST as a paradigm of molecularly targeted therapy 09.10 - 09.50:   Prof. Alexander Levitzki, The Hebrew University of Jerusalem, Israel Targeting the EGFR and the PKB pathway 09.50 - 10.30:   Prof. Sara A. Courtneidge, The Burnham Institute, La Jolla, CA, USA The involvement of Src and its substrates in cancer cell invasion 10.30 - 11.00:   Coffee Session VI   Chair: Prof. Max M. Burger, Chairman Novartis Science Board, Novartis International, Basel, Switzerland 11.00 - 11.40:   Prof. Owen Witte, University of California, Los Angeles, CA, USA Modeling prostate cancer progression and therapy by tissue regeneration 11.40 - 12.20:   Prof. James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets 12.20 - 13.00:   Prof. David Livingston, Dana-Farber Cancer Institute, Boston, MA, USA Kinase shRNA screening in fresh, primary human ovarian cancer cells 13.00 - 14.30:   Lunch Session VII   Chair: Prof. Georges-A. Hollaender, Department Clinical-Biological Sciences, University of Basel, Basel, Switzerland 14.30 - 15.10:   Prof. Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain CDKs and the cell cycle 15.10 - 15.50:   Prof. Adrian Merlo, University Hospital, Basel, Switzerland Translating biology into clinics: the case of glioblastoma 15.50 - 16.30:   Prof. Radek Skoda, Department Clinical-Biological Sciences, University of Basel, Switzerland Mutated JAK2 and myeloproliferative disorders 16.30 - 17.00:   Coffee Session VIII   Chair: Prof. Ruth Chiquet, Friedrich Miescher Institute For Biomedical Research, Basel, Switzerland 17.00 - 17.40:   Prof. Bill Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA, USA Linking somatic genetics alterations in cancer to therapeutics 17.40 - 18.20:   Prof. Michael Stratton, Wellcome Trust Sanger Institute, Hinxton, UK Screen of the full protein kinase gene family for somatic mutations 18.20 - 19.00:   Prof. Victor Velculescu, John Hopkins University School of Medicine, Baltimore, MD, USA Genomic analysis of human cancer 19.00 - 21.00:   Poster session   WEDNESDAY, 6TH DECEMBER 2006: Session IX   Chair: Dr. Juerg Zimmermann, Novartis Institutes for BioMedical Research, Basel, Switzerland 08.30 - 09.10:   Dr. Carlos Garcia-Echeverria, Novartis Institutes for BioMedical Research, Basel, Switzerland Blocking the IGF-IR/PI3K survival signalling pathway in cancer cells 09.10 - 09.50:   Prof. Thomas M. Roberts, Dana-Farber Cancer Institute, Boston, MA, USA Targeting PI3 kinase in cancer 09.50 - 10.30:   Prof. David Barford, Institute of Cancer Research, London, UK Structural basis for activation of B-RAF by oncogenic mutations and PKB/Akt by phosphorylation 10.30 - 11.00:   Coffee Session X   Chair: Prof. Matthias Wymann, Department Clinical-Biological Sciences, University of Basel, Switzerland 11.00 - 11.40:   Prof. Mike Hall, Biozentrum, University of Basel, Basel, Switzerland TOR signalling and control of cell growth 11.40 - 12.20:   Prof. George Thomas, Genome Research Institute, University of Cincinnati Medical School, Cincinnati, OH, USA Targeting TSC with RAD001: The TSC1/2 tumor suppressor and proto-oncogene Rheb in mTOR signalling 12.20 - 13.00:   Dr. Heidi Lane, Novartis Institutes for BioMedical Research, Basel, Switzerland A review of the potential of mTOR inhibitors for the treatment of human cancer 13.00 - 14.00:   Lunch Session XI   Chair: Dr. Jan Hofsteenge, Friedrich Miescher Institute For Biomedical Research, Basel, Switzerland 14.00 - 14.40:   Prof. Michael B. Yaffe, Massachusetts Institute of Technology, Cambridge, MA, USA A novel cell cycle checkpoint kinase pathway that integrates global stress response's and DNA damage 14.40 - 15.20:   Prof. Susan M. Gasser, Friedrich Miescher Institute For Biomedical Research, Basel, Switzerland ATR kinases at sites of DNA damage 15.20 - 16.00:   Prof. Peter J. Parker, CRUK, London Research Institute, London, UK PKC epsilon controls the final committed step in cell division 16.00 - 16.40:   Dr. Jürgen Wagner, Novartis Institutes for BioMedical Research, Basel, Switzerland Protein kinase C inhibition: a novel approach to prevent solid organ rejection 16.40 - 17.10:   Coffee Session XII   Chair: Prof. Kurt Ballmer-Hofer, Paul Scherrer Institute, Villigen, Switzerland 17.10 - 17.50:   Dr. Sandra Jacob, Novartis Institutes for Biomedical Research, Basel, Switzerland Structural biology contributions to tyrosine kinase drug discovery projects 17.50 - 18.30:   Dr. Pascal Furet, Novartis Institutes for BioMedical Research, Basel, Switzerland Protein kinase inhibitors by design 18.30 - 19.10:   Dr. Doriano Fabbro, Novartis Institutes for Biomedical Research, Basel, Switzerland Multitargeted kinase inhibitors: an old concept with a new name? 19.10   Closing Party